Nitya Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nitya Nair has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
Thomas Müller
68 shared publications- Jason John Luke
UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA
58 shared publications - Randy F. Sweis
The University of Chicago 1 Section of Hematology/Oncology, Department of Medicine Chicago, Illinois
58 shared publications Jincheng Wu
52 shared publicationsMarc Pelletier
52 shared publicationsMatthew Ingham
52 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1876556
Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting
Introduction: Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I molecule that functions as an immune checkpoint via inhibitory receptors such as immunoglobulin-like transcript 2 (ILT2), immunoglobulin-like transcript 4 (ILT4) and killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), suppressing anti-tumor immunity. Its prevalence and regulation across solid tumors remain incompletely defined due to low expression, spatial heterogeneity, and detection challenges. Methods: We performed a multimodal target prevalence analysis integrating data from a validated immunohistochemistry (IHC) assay for protein detection and prospective screening data from a phase 1 study of an HLA-G × CD3 T cell bispecific antibody (Clintrials.gov identifier: NCT05769959) with bulk RNA sequencing from early-phase oncology clinical trials. Results: Analysis of 252 patient tumor samples using an investigational HLA-G IHC assay showed that 59.9% were HLA-G positive, with highest prevalence in ovarian cancer (89%), non-small cell lung cancer (NSCLC) (76%), renal cell carcinoma (RCC) (71%), and pancreatic cancer (70%). Expression was generally low to moderate and spatially heterogeneous. Notably, discordance between transcript and protein expression was observed in melanoma, where high mRNA levels were not matched by detectable protein, suggesting post-transcriptional regulation. Prospective screening in a phase 1 cohort confirmed a high target positivity rate (77.5%). At the transcript level, HLA-G expression was enriched in inflamed tumors and correlated with interferon gamma (IFN-γ) signaling, antigen presentation pathways, and effector T-cell markers including cluster of differentiation 8 alpha ( CD8A ), interferon gamma gene ( IFNG ) and granzyme B ( GZMB ). Conclusions: HLA-G appears to be an inducible immune checkpoint associated with IFN-γ-driven immune activation and adaptive resistance. Transcript-protein discordance and spatial heterogeneity highlight the need for protein-level assessment in biomarker development. These findings inform companion diagnostic strategies for HLA-G-directed immunotherapies.
- 24 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1876556
Open AccessMultimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting
Introduction: Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I molecule that functions as an immune checkpoint via inhibitory receptors such as immunoglobulin-like transcript 2 (ILT2), immunoglobulin-like transcript 4 (ILT4) and killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), suppressing anti-tumor immunity. Its prevalence and regulation across solid tumors remain incompletely defined due to low expression, spatial heterogeneity, and detection challenges. Methods: We performed a multimodal target prevalence analysis integrating data from a validated immunohistochemistry (IHC) assay for protein detection and prospective screening data from a phase 1 study of an HLA-G × CD3 T cell bispecific antibody (Clintrials.gov identifier: NCT05769959) with bulk RNA sequencing from early-phase oncology clinical trials. Results: Analysis of 252 patient tumor samples using an investigational HLA-G IHC assay showed that 59.9% were HLA-G positive, with highest prevalence in ovarian cancer (89%), non-small cell lung cancer (NSCLC) (76%), renal cell carcinoma (RCC) (71%), and pancreatic cancer (70%). Expression was generally low to moderate and spatially heterogeneous. Notably, discordance between transcript and protein expression was observed in melanoma, where high mRNA levels were not matched by detectable protein, suggesting post-transcriptional regulation. Prospective screening in a phase 1 cohort confirmed a high target positivity rate (77.5%). At the transcript level, HLA-G expression was enriched in inflamed tumors and correlated with interferon gamma (IFN-γ) signaling, antigen presentation pathways, and effector T-cell markers including cluster of differentiation 8 alpha ( CD8A ), interferon gamma gene ( IFNG ) and granzyme B ( GZMB ). Conclusions: HLA-G appears to be an inducible immune checkpoint associated with IFN-γ-driven immune activation and adaptive resistance. Transcript-protein discordance and spatial heterogeneity highlight the need for protein-level assessment in biomarker development. These findings inform companion diagnostic strategies for HLA-G-directed immunotherapies.
- Open Access
- 14 August 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Early functional reactivity to a CEACAM5 x CD3 T cell bispecific antibody in solid tumors associates with baseline immune contexture rather than target antigen density alone
Clinical translation of T cell bispecific (TCB) therapies in solid tumors is hindered by the immunosuppressive tumor microenvironment and intratumoral heterogeneity, features poorly captured by standard preclinical models. We applied an integrated translational framework, combining humanized mouse models, a patient-derived ex vivo organ culture (EVOC) platform, and Phase 1 clinical trial data (ClinTrials.gov identifier NCT03539484), to define the biologic determinants of functional reactivity to a CEACAM5 x CD3 TCB. In humanized mice bearing CEA-positive tumors, the TCB inhibited tumor growth and increased intratumoral T cell infiltration. EVOC, which preserves native 3D tumor architecture and endogenous tumor immune contexture, revealed rapid TCB-induced secretion of IFNγ, IL-2, TNFα, and IL-10 across colorectal, pancreatic, and non-small cell lung cancer patient tumors, with substantial inter-patient heterogeneity. Higher baseline CD3+ T cell infiltration trended with a greater magnitude of cytokine release in patient tumors treated with the TCB ex vivo versus tumors with lower CD3+ T cell infiltration. Baseline tumor CEA expression did not associate with functional response in EVOC. In the Phase 1 trial, on-treatment peripheral cytokine induction was greater in patients with immune-inflamed or -excluded tumors as compared to those with immune-desert tumors. EVOC recapitulated the high inter-patient functional heterogeneity observed clinically, with a coefficient of variation for IFNγ of 135% in EVOC versus 190% in patients, compared with 52% in humanized mice. These findings suggest that early pharmacodynamic responses to CEACAM5 x CD3 TCB associate with a pre-existing tumor immune state rather than target antigen expression alone and support integration of patient-derived ex vivo models for modeling clinically-relevant pharmacodynamics.
- 14 August 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessEarly functional reactivity to a CEACAM5 x CD3 T cell bispecific antibody in solid tumors associates with baseline immune contexture rather than target antigen density alone
Clinical translation of T cell bispecific (TCB) therapies in solid tumors is hindered by the immunosuppressive tumor microenvironment and intratumoral heterogeneity, features poorly captured by standard preclinical models. We applied an integrated translational framework, combining humanized mouse models, a patient-derived ex vivo organ culture (EVOC) platform, and Phase 1 clinical trial data (ClinTrials.gov identifier NCT03539484), to define the biologic determinants of functional reactivity to a CEACAM5 x CD3 TCB. In humanized mice bearing CEA-positive tumors, the TCB inhibited tumor growth and increased intratumoral T cell infiltration. EVOC, which preserves native 3D tumor architecture and endogenous tumor immune contexture, revealed rapid TCB-induced secretion of IFNγ, IL-2, TNFα, and IL-10 across colorectal, pancreatic, and non-small cell lung cancer patient tumors, with substantial inter-patient heterogeneity. Higher baseline CD3+ T cell infiltration trended with a greater magnitude of cytokine release in patient tumors treated with the TCB ex vivo versus tumors with lower CD3+ T cell infiltration. Baseline tumor CEA expression did not associate with functional response in EVOC. In the Phase 1 trial, on-treatment peripheral cytokine induction was greater in patients with immune-inflamed or -excluded tumors as compared to those with immune-desert tumors. EVOC recapitulated the high inter-patient functional heterogeneity observed clinically, with a coefficient of variation for IFNγ of 135% in EVOC versus 190% in patients, compared with 52% in humanized mice. These findings suggest that early pharmacodynamic responses to CEACAM5 x CD3 TCB associate with a pre-existing tumor immune state rather than target antigen expression alone and support integration of patient-derived ex vivo models for modeling clinically-relevant pharmacodynamics.
- Open Access
- 3 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 1-13
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Immune checkpoint inhibitors (ICIs) are a standard treatment across cancers, yet most patients do not respond, and existing biomarkers generalize poorly across tumor types and therapies. Here we present COMPASS, a pan-cancer foundation model that predicts immunotherapy response from bulk tumor transcriptomes using a concept bottleneck transformer. COMPASS encodes gene expression through 44 biologically grounded immune concepts representing immune cell states, tumor−microenvironment interaction and signaling pathways. Trained on 10,184 tumors across 33 cancer types, COMPASS achieves better average performance than 22 methods across 16 clinical cohorts spanning seven cancers and six ICIs, improving accuracy by 8.5% and area under the precision-recall curve by 15.7% on average across cohorts. COMPASS generalizes to cancer types and treatments not represented during fine-tuning and may inform indication selection and patient stratification. In survival analyses, patients classified by COMPASS as responders had longer overall survival (hazard ratio = 4.7, P < 0.0001). Personalized response maps connect gene expression to immune concepts, identifying programs associated with response and resistance; in immune-inflamed non-responders, COMPASS highlights programs including TGFβ signaling, endothelial exclusion, CD4+ T cell dysfunction and B cell deficiency. COMPASS predicts immunotherapy response and provides hypothesis-generating mechanistic insight for trial design and translational studies.
- 3 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (8) , 1-13
Open AccessGeneralizable AI predicts immunotherapy outcomes across cancers and treatments
Immune checkpoint inhibitors (ICIs) are a standard treatment across cancers, yet most patients do not respond, and existing biomarkers generalize poorly across tumor types and therapies. Here we present COMPASS, a pan-cancer foundation model that predicts immunotherapy response from bulk tumor transcriptomes using a concept bottleneck transformer. COMPASS encodes gene expression through 44 biologically grounded immune concepts representing immune cell states, tumor−microenvironment interaction and signaling pathways. Trained on 10,184 tumors across 33 cancer types, COMPASS achieves better average performance than 22 methods across 16 clinical cohorts spanning seven cancers and six ICIs, improving accuracy by 8.5% and area under the precision-recall curve by 15.7% on average across cohorts. COMPASS generalizes to cancer types and treatments not represented during fine-tuning and may inform indication selection and patient stratification. In survival analyses, patients classified by COMPASS as responders had longer overall survival (hazard ratio = 4.7, P < 0.0001). Personalized response maps connect gene expression to immune concepts, identifying programs associated with response and resistance; in immune-inflamed non-responders, COMPASS highlights programs including TGFβ signaling, endothelial exclusion, CD4+ T cell dysfunction and B cell deficiency. COMPASS predicts immunotherapy response and provides hypothesis-generating mechanistic insight for trial design and translational studies.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Immunohistochemistry of injected and noninjected lesions
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Immunohistochemistry of injected and noninjected lesions
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
T-cell clonal expansion at Cycle 1, Day 8 and Cycle 2, Day 1 relative to pre-treatment, by patient
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
T-cell clonal expansion at Cycle 1, Day 8 and Cycle 2, Day 1 relative to pre-treatment, by patient
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Time on MIW815 treatment according to dose level and indication
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Time on MIW815 treatment according to dose level and indication
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Pre- and on-treatment images of injected lesions from patients with a confirmed or unconfirmed response
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Pre- and on-treatment images of injected lesions from patients with a confirmed or unconfirmed response
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary tables and figure legends
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary tables and figure legends
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
On-treatment changes in NK-cell lineage markers in injected and noninjected lesions
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
On-treatment changes in NK-cell lineage markers in injected and noninjected lesions
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary tables and figure legends
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Supplementary tables and figure legends